Shares of The Medicines Company (Nasdaq: MDCO) were up 24% pre-market after it announced positive top-line results from the first pivotal Phase III clinical trial evaluating the efficacy, safety, and tolerability of PCSK9 drug inclisiran to decrease LDL-cholesterol (LDL-C) through twice-yearly dosing.
The ORION-11 study of inclisiran sodium 300mg met all primary and secondary endpoints with efficacy consistent with findings from Phase I and II studies. The trial showed that inclisiran was well tolerated and confirmed that the safety profile was at least as favorable as that demonstrated in the ORION-1 Phase II and ORION-3 open label extension studies.
Detailed efficacy, tolerability and safety data from ORION-11 will be presented during a late-breaking science session at the European Society of Cardiology’s ESC Congress 2019, Paris, on September 2.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze